Background Next-generation sequencing is used in cancer research to identify somatic and
germline mutations, which can predict sensitivity or resistance to therapies, and may be a …

Next-generation sequencing (NGS) efforts have established catalogs of mutations relevant
to cancer development. However, the clinical utility of this information remains largely …

Background Although large-scale, next-generation sequencing (NGS) studies of cancers
hold promise for enabling precision oncology, challenges remain in integrating NGS with …

The tools of next-generation sequencing (NGS) technology, such as targeted sequencing of
candidate cancer genes and whole-exome and-genome sequencing, coupled with …

With the rapid advancement of sequencing technologies, next generation sequencing (NGS)
analysis has been widely applied in cancer genomics research. More recently, NGS has …

Large efforts dedicated to detect somatic alterations across tumor genomes/exomes are
expected to produce significant improvements in precision cancer medicine. However, high …

Given the success of targeted agents in specific populations it is expected that some degree
of molecular biomarker testing will become standard of care for many, if not all, cancers. To …

Importance Understanding molecular mechanisms of response and resistance to anticancer
therapies requires prospective patient follow-up and clinical and functional validation of both …

Introduction The identification of tumour mutational burden (TMB) as a biomarker of
response to programmed cell death protein 1 (PD-1) immunotherapy has necessitated the …

Background As knowledge of mechanisms that drive the development of cancer grows,
there has been corresponding growth in therapies specific to a mechanism. While these …